Clinical Relevance of Pharmacogenetics in Serotonin Syndrome

Joint Authors

Pandya, Dehuti
Tran, My
Verduzco-Gutierrez, Monica

Source

Case Reports in Psychiatry

Issue

Vol. 2020, Issue 2020 (31 Dec. 2020), pp.1-7, 7 p.

Publisher

Hindawi Publishing Corporation

Publication Date

2020-10-08

Country of Publication

Egypt

No. of Pages

7

Main Subjects

Psychology
Medicine
Psychiatry

Abstract EN

Serotonin syndrome is a predictable life-threatening condition that is caused by serotonergic stimulation of the central and peripheral nervous systems.

A patient’s genetic profile can amplify exposure risk as many serotonergic drugs are metabolized by CYP450 enzymes, and these enzymes may be altered in functionality.

We report a case of an elderly man who presented with serotonin syndrome after a dose change in valproic acid 5 weeks prior.

His medication list consisted of low-dose serotonergic agents, which is unusual as most cases of serotonin syndrome involve higher doses.

A review of his pharmacogenetic profile is presented to retrospectively evaluate the additive risk for serotonin syndrome and implications on resuming serotonergic agents.

American Psychological Association (APA)

Pandya, Dehuti& Tran, My& Verduzco-Gutierrez, Monica. 2020. Clinical Relevance of Pharmacogenetics in Serotonin Syndrome. Case Reports in Psychiatry،Vol. 2020, no. 2020, pp.1-7.
https://search.emarefa.net/detail/BIM-1150937

Modern Language Association (MLA)

Pandya, Dehuti…[et al.]. Clinical Relevance of Pharmacogenetics in Serotonin Syndrome. Case Reports in Psychiatry No. 2020 (2020), pp.1-7.
https://search.emarefa.net/detail/BIM-1150937

American Medical Association (AMA)

Pandya, Dehuti& Tran, My& Verduzco-Gutierrez, Monica. Clinical Relevance of Pharmacogenetics in Serotonin Syndrome. Case Reports in Psychiatry. 2020. Vol. 2020, no. 2020, pp.1-7.
https://search.emarefa.net/detail/BIM-1150937

Data Type

Journal Articles

Language

English

Notes

Includes bibliographical references

Record ID

BIM-1150937